drugset / Trial / NCT05452525

Pharmacokinetics and Safety/Tolerability Profile of CKD-379

NCT05452525

Phase 1 Completed 24 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination

Timeline

Start
2022-07-26
Primary completion
2022-08-27
Completion
2022-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-379 Unknown
Subject D150 Unknown
Subject D745 Unknown
Subject D759 Unknown